ArticleCancer research2023
RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond.
Jie Wu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it
ArticleCancer research2023
Jie Wu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.